Phaseline

Companies › Spyre Therapeutics

Spyre Therapeutics: clinical trials, targets and expected readouts

5 active drug programs in 6 registered trials: 5 Phase 2, 1 Phase 1; Immunology, Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SPY001–Phase 2Ulcerative ColitisJun 2027
SPY002–Phase 2Ulcerative ColitisJun 2027
SPY003–Phase 2Ulcerative ColitisJun 2027
SPY072–Phase 2Hidradenitis Suppurativa (HS); Rheumatoid ArthritisOct 2027
SPY003-207–Phase 1HealthyNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06873724SPY003-207Phase 1HealthyOtherNov 2026
NCT07012395SPY001Phase 2Ulcerative ColitisImmunologyJun 2027
NCT07012395SPY002Phase 2Ulcerative ColitisImmunologyJun 2027
NCT07012395SPY003Phase 2Ulcerative ColitisImmunologyJun 2027
NCT07766005SPY072Phase 2Hidradenitis Suppurativa (HS)ImmunologyOct 2027
NCT07148414SPY072Phase 2Rheumatoid ArthritisImmunologyMar 2028

From the company's SEC filings

Cash and short-term investments of $1.1bn on 2026-09-30; operating cash outflow about $275m a year; runway about 48 months at that burn, to Sep 2030; 3 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 15 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Oruka Therapeutics Palisade Bio Sagimet Biosciences Aclaris Therapeutics Almirall

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.